DDrare: Database of Drug Development for Rare Diseases

58. 肥大型心筋症
［臨床試験数：92，薬物数：126（DrugBank：35），標的遺伝子数：40，標的パスウェイ数：141］

Searched query = "Hypertrophic cardiomyopathy"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = (R)-N-(5-(5-ETHYL-1,2,4-OXADIAZOL-3-YL)-2,3-DIHYDRO-1H-INDEN-1-YL)-1-METHYL-1H-PYRAZOLE-4-CARBOXAMIDE; 1-(2,3,4-Trimethoxybenzyl)piperazine dihydrochloride; Acetylcysteine; Adenosine; Air; Alcohol; Antiarrhythmic drugs; Atorvastatin; BNP; BNP blood sample test; Behavioral: Lifestyle; Bluefish; CAS Name: 1,4-Benzoxazepin-5(2H)-one, 3,4-dihydro-4-(2-pyrimidinylmethyl)-7-[4- (trifluoromethoxy)phenyl] IUPAC Name: 4-(Pyrimidin-2-ylmethyl)-7-[4- (trifluoromethoxy)phenyl]-3,4-dihydro-1,4-benzoxazepin-5(2H)-one; CAS Name: 1,4-Benzoxazepin-5(2H)-one, 3,4-dihydro-4-(2-pyrimidinylmethyl)-7-[4-(trifluoromethoxy)phenyl] IUPAC Name: 4-(Pyrimidin-2-ylmethyl)-7-[4-(trifluoromethoxy)phenyl]-3,4-dihydro-1,4-benzoxazepin-5(2H)-one; CK-3773274; CK-3773274 (10 - 30 mg); CK-3773274 (5 - 15 mg); CK-3773274 - Granules in Capsule; CK-3773274 - Tablets; CT-G20; Candesartan; Carnitine; Cufence; Cyclosporine; Cyclosporine A; Device: Insertable cardiac monitor; Device: Magnetic resonance imaging (MRI) with gadolinium enhancement; Device: Magnetic resonance imaging (MRI) without gadolinium enhancement; Device: Use of bioanalytical assay to monitor plasma levels of perhexiline; Diagnostic Test: Air venous plethysmography; Diagnostic Test: Echocardiography; Diagnostic Test: Electrocardiogram; Diagnostic Test: Exercise Stress Transthoracic Echocardiogram; Diagnostic Test: Holter ECG; Diagnostic Test: Phosphorous Magnetic Resonance Spectroscopy; Diagnostic Test: Upper member arterial Doppler echography with analysis of FMD; Diltiazem; Diovan; Diovan 160 mg; Diovan 40 mg; Diovan 80 mg; Dobutamine; Echo and myocardial contrast echocardiography perfusion imaging; Eleclazine; Endothelial function biomarkers; Entresto; GS-6615 3 mg; GS-6615 3 mg Pink; GS-6615 3 mg White; GS-6615 6 mg; GS-6615 6 mg White; Gadolinium; Gradient; Gutron 2,5mg; Gutron 5mg; Hyperpolarized 13C-Pyruvate; LCZ696; LCZ696 100 mg; LCZ696 200 mg; LCZ696 50 mg; Losartan; Losartan Bluefish 50 mg; MAVACAMTEN; MEK162; MIDODRINE HYDROCHLORIDE; MONITOR; MYK-461; Mangafodipir; Mavacamten; Metoprolol; Metoprolol Succinate; Midodrine; N-acetylcysteine; Nitrate; Other: Exercise echocardiography; Other: Mangafodipir trisodium; Other: Walk distance test; Perhexiline; Perxexiline; Pexsig; Phosphorous; Piperazine; Pirfenidone; Procedure: 3D electrocardiographic mapping (ECM); Procedure: B-lines SE; Procedure: Coronary flow reserve SE; Procedure: Diastolic function SE; Procedure: Echocardiography (TEE); Procedure: Left ventricular contractile reserve SE; Procedure: Left ventricular outflow tract gradient SE; Procedure: Mitral regurgitation SE; Procedure: Pulmonary hemodynamics SE; Procedure: RF catheter ablation; Procedure: trans-right ventricular alcohol septal ablation (TRVASA); Pyrazole; RANEXA; RANEXA*60CPR 500MG R.P.; RANEXA*60CPR 750MG R.P.; RANOLAZINE; Ranexa; Ranolazine; Ranolazine 1000 mg PR tablets; Ranolazine 500 mg PR tablets; Ranolazine 750 mg PR tablets; Ranolazine PR (prolonged-release) 500 mg 1 tablet bis in die and 750 mg 1 tablet bis in die; Regadenoson; SACUBITRIL VALSARTAN; Sacubitril; Sacubitril/Valsartan; Sacubitril/valsartan; Sodium Nitrate; Sodium nitrate; Spironolactone; Treatment BX1514M; Trientine; Trientine Dihydrochloride; Trientine dihydrochloride; Triethylinetetramine dihydrochloride; Trimetazidine; Trimetazidine Dihydrochloride 20mg; Trimetazidine dihydrochloride; VALSARTAN; Valsartan; Vastarel; Vastarel 20mg film coated tablets; [MYK-461]

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01447654 (ClinicalTrials.gov)	November 2011	4/10/2011	Inhibition of the Renin Angiotensin System With Losartan in Patients With Hypertrophic Cardiomyopathy	INHibition of the Renin Angiotensin System in Hypertrophic Cardiomyopathy and the Effect on Ventricular Hypertrophy - a Randomized Intervention Trial With Losartan.	Hypertrophic Cardiomyopathy	Drug: Losartan;Drug: Placebo	Henning Bundgaard	NULL	Completed	18 Years	N/A	Both	130	Phase 2	Denmark
2	EUCTR2011-001191-19-DK (EUCTR)	26/10/2011	12/09/2011	Effects on the heart in patients with hypertophic cardiomyopathy when treated with losartan.	Cardiac effects of inhibition of the renin angiotensin system with losartan in patients with hypertrophic cardiomyopathy.	Hypertrophic cardiomyopathy MedDRA version: 14.0;Level: LLT;Classification code 10020876;Term: Hypertrophic obstructive cardiomyopathy;System Organ Class: 10007541 - Cardiac disorders;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]	Trade Name: Losartan Bluefish 50 mg Product Name: Losartan	Hjertemedicinsk klinik B, 2142, Rigshospitalet	NULL	Not Recruiting			Female: yes Male: yes			Denmark
3	NCT01150461 (ClinicalTrials.gov)	February 2007	22/6/2010	Effect of Losartan in Patients With Nonobstructive Hypertrophic Cardiomyopathy	Effect of Losartan in Patients With Nonobstructive Hypertrophic Cardiomyopathy	Hypertrophic Cardiomyopathy	Drug: losartan;Drug: placebo	Massachusetts General Hospital	NULL	Completed	18 Years	N/A	All	20	Phase 2	United States
4	NCT00001534 (ClinicalTrials.gov)	September 1996	3/11/1999	Long Term Effects of Enalapril and Losartan on Genetic Heart Disease	Double-Blind, Placebo-Controlled Study of the Long Term Effects of Angiotensin Converting Enzyme Inhibition (Enalapril) and Angiotensin II Receptor Blockade (Losartan) on Genetically-Induced Left Ventricular Hypertrophy in Non-Obstructive HCM	Hypertrophic Cardiomyopathy;Left Ventricular Hypertrophy;Myocardial Ischemia	Drug: Losartan	National Heart, Lung, and Blood Institute (NHLBI)	NULL	Completed	N/A	N/A	Both	112	N/A	United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT01447654
(ClinicalTrials.gov)

November 2011

4/10/2011

Inhibition of the Renin Angiotensin System With Losartan in Patients With Hypertrophic Cardiomyopathy

INHibition of the Renin Angiotensin System in Hypertrophic Cardiomyopathy and the Effect on Ventricular Hypertrophy - a Randomized Intervention Trial With Losartan.

Hypertrophic Cardiomyopathy

Drug: Losartan;Drug: Placebo

Henning Bundgaard

NULL

Completed

18 Years

N/A

Both

130

Phase 2

Denmark

EUCTR2011-001191-19-DK
(EUCTR)

26/10/2011

12/09/2011

Effects on the heart in patients with hypertophic cardiomyopathy when treated with losartan.

Cardiac effects of inhibition of the renin angiotensin system with losartan in patients with hypertrophic cardiomyopathy.

Hypertrophic cardiomyopathy
MedDRA version: 14.0;Level: LLT;Classification code 10020876;Term: Hypertrophic obstructive cardiomyopathy;System Organ Class: 10007541 - Cardiac disorders;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]

Trade Name: Losartan Bluefish 50 mg
Product Name: Losartan

Hjertemedicinsk klinik B, 2142, Rigshospitalet

NULL

Not Recruiting

Female: yes
Male: yes

Denmark

NCT01150461
(ClinicalTrials.gov)

February 2007

22/6/2010

Effect of Losartan in Patients With Nonobstructive Hypertrophic Cardiomyopathy

Hypertrophic Cardiomyopathy

Drug: losartan;Drug: placebo

Massachusetts General Hospital

NULL

Completed

18 Years

N/A

All

Phase 2

United States

NCT00001534
(ClinicalTrials.gov)

September 1996

3/11/1999

Long Term Effects of Enalapril and Losartan on Genetic Heart Disease

Double-Blind, Placebo-Controlled Study of the Long Term Effects of Angiotensin Converting Enzyme Inhibition (Enalapril) and Angiotensin II Receptor Blockade (Losartan) on Genetically-Induced Left Ventricular Hypertrophy in Non-Obstructive HCM

Hypertrophic Cardiomyopathy;Left Ventricular Hypertrophy;Myocardial Ischemia

Drug: Losartan

National Heart, Lung, and Blood Institute (NHLBI)

NULL

Completed

N/A

Both

112

N/A

United States